Intellipharmaceutics signs generics supply deal with Mallinckrodt
Canada-based Intellipharmaceutics International (TSX:I) has entered into a license and commercial supply agreement with Mallinckrodt, granting the latter an exclusive license to market, sell and distribute in the USA three extended release drug product candidates for which Intellipharmaceutics has Abbreviated New Drug Applications (ANDAs) filed with the US Food and Drug Administration.
The three generics are:
- quetiapine fumarate extended-release tablets (a generic of AstraZeneca’s Seroquel XR) - ANDA tentatively approved by FDA this month;
- desvenlafaxine extended-release tablets (a generic of Pfizer’s Pristiq) - ANDA under FDA review; and
- lamotrigine extended-release tablets (a generic of GlaxoSmithKline’s Lamictal XR) - ANDA under FDA review.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Generics
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze